#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Proteus syndrome Chronic granulomatous disease Pulmonary alveolar haemorrhage Ataxia telangiectasia Myotonia Brain injury Tourette's disorder Ovarian epithelial cancer Malformation venous Thymic carcinoma Gastrointestinal neuroendocrine tumour Infantile spasms Penile squamous cell carcinoma Hepatitis D Osteosarcoma recurrent More trials…

    Learn about Rare Diseases

    Hereditary angioedema – Treatment Lymphangioma Sarcoidosis Lysosomal storage disorder Glycogen storage disease type V – Basic Information Kearns-Sayre syndrome – Life with Disease Short-bowel syndrome – Diagnostics Acute respiratory distress syndrome – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Trials in Disease Hairy cell leukaemia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tinengotinib Sufentanil Paracetamol Ph. Eur. L-PROLINE Lysine Acetate Tebipenem Pivoxil Hydrobromide Imsidolimab SGT-003 FG001 Gen1047 Quizartinib Dihydrochloride Sarilumab Dobutamine Ralinepag Pegenzileukin Sodium Alginate Carbamazepine (Ph. Eur.) Enasidenib Mesilate Jab-21822 Betamethasone Dipropionate More therapies…

    Learn about Your Condition

    Epileptic encephalopathy Guttate psoriasis Skin neoplasm excision Retinoblastoma Injection site pain Incisional hernia Pneumonia Congenital pseudarthrosis T-cell type acute leukaemia Thermal burn Post-traumatic headache Hydrocele Haemoglobinuria Elderly Ependymoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Ovarian cancer stage IV

  • Study on Letrozole vs. Chemotherapy (Carboplatin and Paclitaxel) for Patients with Advanced Low-Grade Serous Ovarian Cancer with Hormone Receptors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer stage III
    • Ovarian cancer stage IV
    Investigated Drugs:
    • Carboplatin
    • Letrozole
    • Paclitaxel
    Czechia Italy

  • Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Niraparib
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia Germany Italy Spain

  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Ds-3939A
    Belgium France Spain

  • Study on the Effects of Tinzaparin on Biomarkers in Advanced Ovarian Cancer Patients Receiving Chemotherapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer stage III
    • Ovarian cancer stage IV
    • Ovarian cancer
    Investigated Drugs:
    • Tinzaparin Sodium
    Sweden

  • Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Filgrastim
    • Bevacizumab
    • Carboplatin
    France Italy The Netherlands

  • Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    Belgium Czechia Denmark Finland France Germany +7

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!